Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × abemaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 80 Neoplasm Metastasis 21 Brain Neoplasms 11 Neoplasms 10 Prostatic Neoplasms 9 Endometrial Neoplasms 9 Carcinoma, Non-Small-Cell Lung 8 Glioblastoma 7 Ovarian Neoplasms 6 Triple Negative Breast Neoplasms 5 Glioma 5 Colorectal Neoplasms 5 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma, Ewing 3 Osteosarcoma 3 Multiple Myeloma 3 Meningioma 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Unilateral Breast Neoplasms 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Oligodendroglioma 2 Neuroblastoma 2 Neoplasms by Site 2 Mesothelioma, Malignant 2

Interventions

Cyclophosphamide 20 blinatumomab 16 fludarabine 13 Cytarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 9 Rituximab 7 Dexamethasone 7 Methotrexate 6 Lenalidomide 6 Daunorubicin 6 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Mercaptopurine 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Cladribine 3 Busulfan 3 Asparaginase 3 tislelizumab 2 tisagenlecleucel 2 thymoglobulin 2 pembrolizumab 2 palbociclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡